Head-to-head comparison
| Property | Liraglutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~13 hours | ~5 days |
| Mol. Weight | 3,751.2 Da | 4,813.45 Da |
| Side Effects | Nausea (39%), Diarrhea, Constipation | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Receptor targets: Liraglutide is a GLP-1 receptor agonist only; tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Weight loss efficacy: Tirzepatide (15 mg) achieved approximately 22.5% weight loss at 72 weeks; liraglutide (3.0 mg) achieved approximately 8% at 56 weeks in the SCALE trial.
- Dosing frequency: Liraglutide requires daily subcutaneous injection; tirzepatide requires weekly subcutaneous injection.
- Half-life: Liraglutide has a half-life of approximately 13 hours (requiring daily dosing); tirzepatide has a half-life of approximately 5 days (supporting weekly dosing).
- Manufacturer: Liraglutide is made by Novo Nordisk (Victoza/Saxenda); tirzepatide is made by Eli Lilly (Mounjaro/Zepbound).
- Market generation: Liraglutide was FDA-approved for diabetes in 2010 and obesity in 2014; tirzepatide was approved for diabetes in 2022 and obesity in 2023.
- HbA1c reduction: Tirzepatide shows superior HbA1c lowering compared to liraglutide in diabetes studies.
The verdict
Tirzepatide is the clearly superior option by modern clinical metrics: nearly three times the weight loss, weekly versus daily dosing, and dual receptor targeting. Liraglutide remains available and may be appropriate when tirzepatide is unavailable, contraindicated, or not covered by insurance. However, liraglutide is increasingly superseded by both semaglutide and tirzepatide in clinical practice.
Frequently asked questions
Yes, substantially. Tirzepatide produces approximately 22.5% body weight loss versus liraglutide's approximately 8%. Tirzepatide also requires only weekly injection compared to liraglutide's daily injection. Tirzepatide represents a generational advance in GLP-1-based therapy.
Switching should be done under physician guidance. The typical approach is to stop liraglutide and start tirzepatide at the initial dose (2.5 mg weekly), then titrate up. There is no direct dose equivalence between the two medications.
Liraglutide may still be used when tirzepatide or semaglutide are unavailable due to supply shortages, not covered by insurance, or when a prescriber prefers a shorter-acting agent for clinical reasons. Its longer market track record also provides more long-term safety data.
No, liraglutide is a GLP-1-only agonist. Tirzepatide's dual GIP/GLP-1 mechanism is believed to account for its superior efficacy, as GIP receptor activation enhances insulin sensitivity and fat metabolism beyond what GLP-1 alone achieves.
Both cause GI side effects (nausea, vomiting, diarrhea) as class effects. Rates are broadly comparable, though daily dosing with liraglutide means daily potential for injection site reactions versus weekly with tirzepatide. Individual tolerance varies.